

STIC-Biotech/ChemLib

167640

From: Chan, Christina
Sent: Tuesday, October 04, 2005 9:59 AM
To: Nguyen, Quang (AU1632); STIC-Biotech/ChemLib
Subject: RE: RUSH sequence search request for 10/018392

Please rush. Thanks Chris

Chris Chan
TC 1600 New Hire Training Coordinator and SPE 1644
(571)-272-0841
Remsen, 3E89

-----Original Message-----

From: Nguyen, Quang (AU1632)
Sent: Tuesday, October 04, 2005 9:34 AM
To: Chan, Christina
Subject: RUSH sequence search request for 10/018392

Good morning,

I would like to request a rush sequence search for the above application because it would like to act on this amended case this bi-week.

Please search:

SEQ ID NO:3

against commerical, issued and pending US patent application databases.

I am in AU 1633, my mailbox is in REM-2C70.

THANK YOU.

Searcher: _____
Searcher Phone: _____
Date Searcher Picked up: 10/14/05
Date completed: 10/16/05
Searcher Prep Time: _____
Online Time: _____

Type of Search
NA# 1 AA# _____
S/L: _____ Oligomer: _____
Encode/Transl: _____
Structure #: _____ Text: _____
Inventor: _____ Litigation: _____

Vendors and cost where applicable
STN: _____
DIALOG: _____
QUESTEL/ORBIT: _____
LEXIS/NEXIS: _____
SEQUENCE SYSTEM: Def
WWW/Internet: _____
Other (Specify): _____

Welcome to DialogClassic Web(tm)

Dialog level 05.06.01D
Last logoff: 29sep05 12:36:09
Logon file001 06oct05 13:25:22

*** ANNOUNCEMENT ***

--UPDATED: Important Notice to Freelance Authors--
See HELP FREELANCE for more information

NEW FILES RELEASED

***Computer and Information Systems Abstracts (File 56)
***Electronics and Communicationss Abstracts (File 57)
***Solid State and Superconductivity Abstracts (File 68)
***ANTE: Abstracts in New Technologies (File 60)
***Civil Engineering Abstracts (File 61)
***Aluminium Industry Abstracts (File 33)
***Ceramic Abstracts/World Ceramic Abstracts (File 335)
***CSA Life Sciences Abstracts (File 24)
***Corrosion Abstracts (File 46)
***Materials Business File (File 269)
***Engineered Materials Abstracts (File 293)
***CSA Aerospace & High Technology Database (File 108)
***CSA Technology Research Database (File 23)
***METADEX(r) (File 32)
***FDAnews (File 182)
***German Patents Fulltext (File 324) ***
RESUMED UPDATING
***Canadian Business and Current Affairs (262)
***CorpTech (559)

Chemical Structure Searching now available in Prous Science Drugs
of the Future (F453), IMS R&D Focus (F445), Beilstein Facts (F390),
and Derwent Chemistry Resource (F355).

>>> Enter BEGIN HOMEBASE for Dialog Announcements <<<
>>> of new databases, price changes, etc. <<<

KWIC is set to 50.
HILIGHT set on as ' '
* * *

File 1:ERIC 1966-2004/Jul 21
(c) format only 2004 Dialog
*File 1: Updates to resume in the next few days. Watch for
further details.

Set Items Description
--- -----

Cost is in DialUnits
?

B 155, 159, 5, 73
06oct05 13:25:41 User259876 Session D805.1
\$0.79 0.227 DialUnits File1
\$0.79 Estimated cost File1
\$0.08 INTERNET
\$0.87 Estimated cost this search
\$0.87 Estimated total session cost 0.227 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 155:MEDLINE(R) 1951-2005/Oct 05

(c) format only 2005 Dialog

File 159:Cancerlit 1975-2002/Oct

(c) format only 2002 Dialog

***File 159: Cancerlit is no longer updating.**

Please see HELP NEWS159.

File 5:Biosis Previews(R) 1969-2005/Oct W1

(c) 2005 BIOSIS

File 73:EMBASE 1974-2005/Oct 06

(c) 2005 Elsevier Science B.V.

Set	Items	Description
---	-----	-----

?

S (FACTOR (W) IX) OR HFIX) (S) ("3' UTR")

>>>Unmatched parentheses

?

S ((FACTOR (W) IX) OR HFIX) (S) ("3' (W) UTR")

2614744 FACTOR

72257 IX

11199 FACTOR(W) IX

205 HFIX

0 3' (W) UTR

S1 0 ((FACTOR (W) IX) OR HFIX) (S) ("3' (W) UTR")

?

S ((FACTOR (W) IX) OR HFIX) AND ("3' (W) UTR")

2614744 FACTOR

72257 IX

11199 FACTOR(W) IX

205 HFIX

0 3' (W) UTR

S2 0 ((FACTOR (W) IX) OR HFIX) AND ("3' (W) UTR")

?

S ((FACTOR (W) IX) OR HFIX) (S) (UTR)

2614744 FACTOR

72257 IX

11199 FACTOR(W) IX

205 HFIX

13482 UTR

S3 8 ((FACTOR (W) IX) OR HFIX) (S) (UTR)

?

RD

...completed examining records

S4 6 RD (unique items)

?

S S4 AND VECTOR

6 S4

308645 VECTOR

S5 3 S4 AND VECTOR

?

T S5/3,K/ALL

5/3,K/1 (Item 1 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2005 Dialog. All rts. reserv.

14654115 PMID: 12473656

Limitation in use of heterologous reporter genes for gene promoter analysis. Silencer activity associated with the chloramphenicol acetyltransferase reporter gene.

Zhang Kezhong; Kurachi Sumiko; Kurachi Kotoku

Department of Human Genetics, University of Michigan Medical School, Ann Arbor, Michigan 48109-0618, USA.

Journal of biological chemistry (United States) Feb 14 2003, 278 (7)

p4826-30, ISSN 0021-9258 Journal Code: 2985121R

Contract/Grant No.: 5-P60-AR-20557; AR; NIAMS; 5P60 DK20572; DK; NIDDK; HL38644; HL; NHLBI; HL64522; HL; NHLBI; M01-RR-00042; RR; NCRR

Publishing Model Print-Electronic

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

... specific parts of the basal promoter or further upstream regions. In this study, we carried out a systematic study on human blood coagulation factor IX (**hFIX**) and anti-coagulant protein C (hPC) genes, previously shown to have silencer activities associated with their 5'-flanking regions containing promoter sequences. With newly constructed chloramphenicol acetyltransferase (CAT) reporter vectors carrying **hFIX** or hPC gene promoter sequences, we confirmed the strong silencer activities associated with the regions nt -1895 through nt -416 of the **hFIX** gene or with the region nt -802 through nt -82 of the hPC gene. However, no such silencer activities associated with the specific regions were found when autologous **hFIX** cDNA, **hFIX** minigenes, or hPC minigenes were used as reporters in the expression **vector** system. Relative levels of CAT, **hFIX** , and hPC proteins produced in the transient assays correlated well with their mRNA levels. Human FIX minigene constructs containing a simian virus 40 (SV40) 3'-untranslated region (**UTR**) taken from the CAT reporter gene showed no silencer activity, indicating that SV40 3'- **UTR** sequence of the CAT reporter gene does not contribute to the silencer activity. Expression vectors constructed with the beta-galactosidase gene under the control of **hFIX** gene promoter sequences also showed no silencer activity associated with the region nt -1895 through nt -416. These findings indicate that silencer activities associated with...

5/3,K/2 (Item 1 from file: 5)

DIALOG(R) File 5:Biosis Previews(R)

(c) 2005 BIOSIS. All rts. reserv.

0014211015 BIOSIS NO.: 200300169734

Limitation in use of heterologous reporter genes for gene promoter analysis. Silencer activity associated with the chloramphenicol acetyltransferase reporter gene.

AUTHOR: Zhang Kezhong; Kurachi Sumiko; Kurachi Kotoku (Reprint)

AUTHOR ADDRESS: Age Dimension Research Center, Higashi 1-1-1, The AIST Tsukuba Central 4th Site, Tsukuba, Ibaraki, 305-8562, Japan**Japan

AUTHOR E-MAIL ADDRESS: kkurachi@umich.edu

JOURNAL: Journal of Biological Chemistry 278 (7): p4826-4830 February 14, 2003 2003

MEDIUM: print

ISSN: 0021-9258

DOCUMENT TYPE: Article

RECORD TYPE: Abstract
LANGUAGE: English

...ABSTRACT: specific parts of the basal promoter or further upstream regions. In this study, we carried out a systematic study on human blood coagulation factor IX (**hFIX**) and anti-coagulant protein C (hPC) genes, previously shown to have silencer activities associated with their 5'-flanking regions containing promoter sequences. With newly constructed chloramphenicol acetyltransferase (CAT) reporter vectors carrying **hFIX** or hPC gene promoter sequences, we confirmed the strong silencer activities associated with the regions nt -1895 through nt -416 of the **hFIX** gene or with the region nt -802 through nt -82 of the hPC gene. However, no such silencer activities associated with the specific regions were found when autologous **hFIX** cDNA, **hFIX** minigenes, or hPC minigenes were used as reporters in the expression **vector** system. Relative levels of CAT, **hFIX** , and hPC proteins produced in the transient assays correlated well with their mRNA levels. Human FIX minigene constructs containing a simian virus 40 (SV40) 3'-untranslated region (**UTR**) taken from the CAT reporter gene showed no silencer activity, indicating that SV40 3'- **UTR** sequence of the CAT reporter gene does not contribute to the silencer activity. Expression vectors constructed with the beta-galactosidase gene under the control of **hFIX** gene promoter sequences also showed no silencer activity associated with the region nt -1895 through nt -416. These findings indicate that silencer activities associated with...

5/3,K/3 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2005 BIOSIS. All rts. reserv.

0013122043 BIOSIS NO.: 200100293882

A nonviral approach: Long-term and therapeutic level human factor IX gene expression due to retention of optimal hFIX plasmids in hepatocytes after naked DNA transfer

AUTHOR: Miao Carol H (Reprint); Thompson Arthur R (Reprint); Loeb Keith R; Ye Xin (Reprint)

AUTHOR ADDRESS: Dept. of Medicine, Puget Sound Blood Center and University of Washington, Seattle, WA, USA**USA

JOURNAL: Blood 96 (11 Part 1): p210a November 16, 2000 2000

MEDIUM: print

CONFERENCE/MEETING: 42nd Annual Meeting of the American Society of Hematology San Francisco, California, USA December 01-05, 2000; 20001201

SPONSOR: American Society of Hematology

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Abstract; Meeting Poster

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: It was found that **hFIX** plasmids containing hepatic locus control region (ApoE-HCR), alpha1-antitrypsin promoter, **hFIX** cDNA, a portion of **hFIX** first intron, and a polyadenylation signal (from either bovine growth hormone or **hFIX** 3'- **UTR**) produced high level gene expression in mouse livers. Rapid tail vein injection of 20 mug plasmids in a large fluid volume produced 10mug/ml of **hFIX** protein (normal=5mug/ml) on the first day, which subsequently decreased to lower levels (Miao et al. (2000) Mol. Ther. 1, 522-532). Very interestingly, the plasma **hFIX** concentrations stabilized at 7-8 weeks in the range from 0.5 to 2 mug/ml (therapeutic for treating hemophilia B). These levels were maintained for over one year (duration of the experiments).

Southern analyses showed that majority of the DNA were taken up by the liver. The mount of **vector** DNA retained in the cells peaked 1 day post injection, then declined and stabilized at a constant level from mice infused by either high-expressing, or low-expressing plasmids. Restriction analyses showed that most of the **vector** DNA stayed in the same episomal forms as the original plasmid. RT-PCR analyses showed that the transcripts were only observed in the liver. The...

...No significant differences were observed between plasmid injection and saline only control. These data established the foundation towards developing nonviral gene transfer strategy with optimal **hFIX** plasmids for the treatment of hemophilia B.

?

Set	Items	Description
S1	0	((FACTOR (W) IX) OR HFIX) (S) ("3' (W) UTR")
S2	0	((FACTOR (W) IX) OR HFIX) AND ("3' (W) UTR")
S3	8	((FACTOR (W) IX) OR HFIX) (S) (UTR)
S4	6	RD (unique items)
S5	3	S4 AND VECTOR

?

S S4 NOT S5

6 S4

3 S5

S6 3 S4 NOT S5

?

T S6/3,K/ALL

6/3,K/1 (Item 1 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2005 Dialog. All rts. reserv.

16328825 PMID: 15590401

Molecular characterization of hemophilia B in North Indian families: identification of novel and recurrent molecular events in the factor IX gene.

Mahajan Anubha; Chavali Sreenivas; Kabra Madhulika; Chowdhury Madhumita Roy; Bharadwaj Dwaipayan

Functional Genomics Unit, Institute of Genomics and Integrative Biology, CSIR, Delhi, India.

Haematologica (Italy) Dec 2004, 89 (12) p1498-503, ISSN 1592-8721
Journal Code: 0417435

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: In Process

... patients. DESIGN AND METHODS: Polymerase chain reaction (PCR) amplification and direct sequencing of all regions of likely functional significance- the coding regions, promoter, the 5' **UTR**, the splice junctions and parts of the 3' **UTR** of the **factor IX** gene was done in 18 families carrying a severe form of hemophilia B. RESULTS: We identified 10 point mutations (including 2 novel ones); one novel...

6/3,K/2 (Item 2 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2005 Dialog. All rts. reserv.

12980979 PMID: 10933977

Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro.

Miao C H; Ohashi K; Patijn G A; Meuse L; Ye X; Thompson A R; Kay M A
Department of Medicine and Puget Sound Blood Center, University of Washington, Seattle 98195, USA.

Molecular therapy - the journal of the American Society of Gene Therapy (UNITED STATES) Jun 2000, 1 (6) p522-32, ISSN 1525-0016
Journal Code: 100890581

Contract/Grant No.: DK49022; DK; NIDDK; HL09754; HL; NHLBI; HL53682; HL; NHLBI

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

... was observed in the in vivo studies. We found that a plasmid containing the apolipoprotein E locus control region (HCR), human alpha1-antitrypsin (hAAT) promoter, **hFIX** minigene (hFIXmg) sequence including a portion of the first intron (intron A), 3'-untranslated region (3'- **UTR**), and a bovine growth hormone polyadenylation signal (bpA) produced the highest serum level of human **factor IX** , reaching 18 microg/ml (normal = 5 microg/ml) 1 day after injection. Although most of the plasmid DNAs resulted in transient gene expression, inclusion of an intron, a polyadenylation signal from either the 1.7-kb 3'- **UTR** or the 0.3-kb bpA, and the HCR resulted in persistent and therapeutic levels of **hFIX** gene expression, ranging from 0.5 to 2 microg/ml (10 to 40% of normal) for 225 days (length of experiment). These data underscore the...

6/3,K/3 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2005 BIOSIS. All rts. reserv.

0013128621 BIOSIS NO.: 200100300460

Genetic mechanisms of age regulation of the anticoagulant protein C gene and conversion of the age regulatory pattern of protein C to that of factor X

AUTHOR: Zhang K-Z (Reprint); Kurachi S (Reprint); Kurachi K (Reprint)

AUTHOR ADDRESS: Human Genetics, University of Michigan Medical School, Ann Arbor, MI, USA**USA

JOURNAL: Blood 96 (11 Part 1): p564a-565a November 16, 2000 2000

MEDIUM: print

CONFERENCE/MEETING: 42nd Annual Meeting of the American Society of Hematology San Francisco, California, USA December 01-05, 2000; 20001201

SPONSOR: American Society of Hematology

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Abstract

LANGUAGE: English

...ABSTRACT: in humans increases with advancing age, which may have substantial clinical importance. Towards understanding this phenomenon, we recently determined the age-regulatory mechanisms of the **hFIX** gene, identifying two elements, AE5' and AE3', essential for recapitulating

physiological age-associated patterns of **hFIX** gene expression (Kurachi et al., Science 1999; 285: 739-743). We now report the genetic mechanisms of age regulation of the human PC (hPC) gene...

...composed of the promoter region up to nucleotide -82, -802, -849 or -1462, coding region with the 1st intron, and the complete 3' untranslated region (**UTR**) with a part of the 3' flanking sequence, were constructed, tested in vitro and used for construction of transgenic mice. These minigenes showed similar transient...

...and -82hPCm1 showed dramatic declines in hPC expression over puberty, thus identifying a specific AE5'-like element, in the natural hPC gene. Animals with an **hFIX** AE5' inserted at the 5' end of -82hPCm1 (AE5'/-82hPCm1) showed age-stable hPC expression and pre-pubertal hPC levels similar to -82hPCm1. With AE3' inserted in the middle of the 3' **UTR** , minigene, -1462hPCm1 gave an age-associated increase in hPC expression, completely mimicking the age regulation of the **hFIX** gene. Thus, we now have established the age-regulatory mechanisms of the hPC gene and the functional universality of AE5' and AE3'.

?

Set	Items	Description
S1	0	((FACTOR (W) IX) OR HFIX) (S) ("3' (W) UTR")
S2	0	((FACTOR (W) IX) OR HFIX) AND ("3' (W) UTR")
S3	8	((FACTOR (W) IX) OR HFIX) (S) (UTR)
S4	6	RD (unique items)
S5	3	S4 AND VECTOR
S6	3	S4 NOT S5

?

S (VECTOR) (S) (HFIX (W) GENE)

	308645	VECTOR
	205	HFIX
	2759039	GENE
S7	39	(VECTOR) (S) (HFIX (W) GENE)

?

S S7 NOT PY>1999

	39	S7
	9154551	PY>1999
S8	12	S7 NOT PY>1999

?

RD

...completed examining records

S9	7	RD (unique items)
----	---	-------------------

?

T S9/3,K/ALL

9/3,K/1 (Item 1 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2005 Dialog. All rts. reserv.

12612895 PMID: 10465892

[Splicing and stability of intron in the expression retroviral vector with human clotting factor IX]

Xing Y N; Lu D R; Gao X B; Qiu X F; Xue J L

Institute of Genetics, Fudan University, Shanghai.

Yi chuan xue bao = Acta genetica Sinica (CHINA) Dec 1998, 25 (6)
p471-7, ISSN 0379-4172 Journal Code: 7900784
Publishing Model Print
Document type: Journal Article ; English Abstract
Languages: CHINESE
Main Citation Owner: NLM
Record type: MEDLINE; Completed

... two forward-orientation retroviral vectors: G1NaC-i-IX contains the exogenous intron from IL-2, and G1NaC-i'-IX contains the truncated intron I from **hFIX gene**, covering the splicing donor and acceptor sequences. RT-PCR result indicated that intron in the forward-orientation retroviral **vector** was spliced after packaging in PA317. Then, reverse-orientation retroviral vectors G1NaC-i'-IXR and G1NaPAIXi' BAM were constructed, in which the reverse and complimentary sequences of **hFIX gene** with intron appeared in retroviral RNA. RT-PCR assay combined with ELISA test indicated that intron was retained after packaging and **hFIX gene** with intron constructed in the reverse-orientation retroviral **vector** can be transduced intact and expressed hFIX at a high level in vitro.

9/3,K/2 (Item 2 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2005 Dialog. All rts. reserv.

11976433 PMID: 9261559

Increment of hFIX expression with endogenous intron 1 in vitro.
Zheng B; Qiu X Y; Tan M; Xing Y N; Lo D; Xue J L; Qiu X F
Institute of Genetics, Eudan Univerisity, Shanghai.
Cell research (CHINA) Jun 1997, 7 (1) p21-9, ISSN 1001-0602
Journal Code: 9425763
Publishing Model Print
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

... with endogenous intron 1 sequence. hFIX minigene was obtained with middle sequence truncated intron 1 inserted into the relative site of hFIX cDNA, and plasmid **vector** pKG5i'IX, retroviral **vector** G1NaCi'IX were constructed. These vectors were transduced into target cells of PA317, C2C12, primary rabbit skin fibroblasts (RSF) and primary human skin fibroblasts (HSF...

... order to study the application of hFIX minigene in the retroviral-mediated gene transfer system and refrain from intron splicing during viral production, a retroviral **vector** G1NaCi'IXR with reversely inserted hFIX minigene expression cassette was constructed. The expression level of reverse constructor in PA317 cells was 390 ng/10(6...

... PCR detection of HT/G1NaCi'IXR cells infected with PA317/G1NaCi'IXR supernatant confirmed the existence of intron 1 sequence. These results suggested that expression **vector** with forward-inserted intron1-carrying hFIX expression cassette can be used in directed gene transfer, but when using the retroviral-mediated gene transfer system, reversely...

9/3,K/3 (Item 3 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2005 Dialog. All rts. reserv.

11922552 PMID: 9264782

[Genetic therapy for hemophiliacs--therapeutic potential and technological limits]

Therapie genique des hemophilies--potentialites therapeutiques et limitations technologiques.

Michou A I; Christ M; Pavirani A; Mehtali M

Transgene S.A., Strasbourg, France.

Transfusion clinique et biologique - journal de la Societe francaise de transfusion sanguine (FRANCE) 1997, 4 (3) p251-61, ISSN 1246-7820

Journal Code: 9423846

Publishing Model Print

Document type: Journal Article; Review; Review, Tutorial ; English Abstract

Languages: FRENCH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

... vivo various recombinant adenovirus vectors expressing human FIX. Intravenous administration of this vector into various strains of immunocompetent and immunodeficient mice led to an efficient **hFIX gene** transfer in liver and lung. As a consequence, the hFIX protein was correctly produced and secreted at high levels in the blood of the treated ...

9/3,K/4 (Item 4 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2005 Dialog. All rts. reserv.

11575256 PMID: 8886845

Construction of human factor IX expression vectors in retroviral vector frames optimized for muscle cells.

Wang J M; Zheng H; Sugahara Y; Tan J; Yao S N; Olson E; Kurachi K

Department of Human Genetics, University of Michigan Medical School, Ann Arbor 48109, USA.

Human gene therapy (UNITED STATES) Sep 10 1996, 7 (14) p1743-56, ISSN 1043-0342 Journal Code: 9008950

Contract/Grant No.: 5-P60-AR20557; AR; NIAMS; HL 38644; HL; NHLBI; HL 53713; HL; NHLBI

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

... contained a hFIX cDNA or hFIX minigene (hIXm1 or hIXm2) derived from the hFIX cDNA by insertion of a shortened first intron sequence of the **hFIX gene**. Regardless of the promoter and **vector** frame used, both hIXm1 and hIXm2 gave 10- to 14-fold higher hFIX expression compared to those with hFIX cDNA. Internal hFIX transcriptional control units...

... As assayed with myotubes in culture, the general order of hFIX expression activity of various promoters with four copies of Me in the three different **vector** frames was beta A280 approximately beta A200 > Mg353 > Mg1031 approximately RSV approximately CO650 approximately alpha A775 > CO1250. One exception was that CO650 showed significantly less...

...components, a group of pdLi vectors consisting of beta A200, two to four copies of Me, and hIXm2 was identified to have the optimal basic **vector** structure to be used in retrovirus for hFIX expression in differentiated

skeletal muscle cells. The present studies provide the critical first step for establishing a highly refined hemophilia B gene therapy based on skeletal muscle-targeted **hFIX** gene transfer.

9/3,K/5 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)
(c) 2005 BIOSIS. All rts. reserv.

0012561068 BIOSIS NO.: 200000279381

Skeletal muscle-specific expression of human blood coagulation factor IX rescues factor IX deficiency mouse by AAV-mediated gene transfer

AUTHOR: Lai Lihui (Reprint); Chen Li (Reprint); Wang Jianmin; Zhou Hong; Lu Daru (Reprint); Wang Qi (Reprint); Gao Xiaobo (Reprint); Qiu Xinfang (Reprint); Xue Jinglun (Reprint)

AUTHOR ADDRESS: Institute of Genetics, Fudan University, Shanghai, 200433, China**China

JOURNAL: Science in China Series C Life Sciences 42 (6): p628-634 Dec., 1999 1999

MEDIUM: print

ISSN: 1006-9305

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: The efficacy of recombinant adeno-associated virus (AAV) vector to deliver and express human blood clotting factor IX (**hFIX**) gene in skeletal muscle of coagulation factor IX deficiency mouse strain (FactorIX-knockout) is evaluated. The muscle creatine kinase enhancer (MCK) and beta-actin promoter (betaA...
...to drive the hFIX minigene (hFIXml), which was flanked by AAV inverted terminal repeats (ITRs). Following intramuscular injection of high titer (2.5 X 10¹¹ **vector** genomes/mL) of rAAV, increased hFIX expression (256 ng/mL of plasma) was achieved. The time course of hFIX expression demonstrated that the expression level...

9/3,K/6 (Item 2 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)
(c) 2005 BIOSIS. All rts. reserv.

0011789002 BIOSIS NO.: 199900048662

Expression and regulation of hFIX minigene and cDNA driven by beta-casein gene in mouse mammary gland

AUTHOR: Zhang Kezhong; Jiang Peihong (Reprint); Lu Daru (Reprint); Huang Weida; Chen Li; Xue Jinglun (Reprint); Qiu Xinfang (Reprint)

AUTHOR ADDRESS: Inst. Genet., Fudan Univ., Shanghai 200433, China**China

JOURNAL: Science in China Series C Life Sciences 41 (4): p406-412 Aug., 1998 1998

MEDIUM: print

ISSN: 1006-9305

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

...ABSTRACT: and intron 1 of beta-casein gene had an effect on the tissue specific expression. The expression level in mouse milk injected with hFIX minigene **vector** containing hFIX endogenous intron 1 was increased by above 3 times of that injected with hFIX cDNA **vector** .

9/3,K/7 (Item 1 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2005 Elsevier Science B.V. All rts. reserv.

06909878 EMBASE No: 1997194320

Gene therapy for hemophiliacs - Therapeutic possibilities and technological limits

THERAPIE GENIQUE DES HEMOPHILIES - POTENTIALITES THERAPEUTIQUES ET LIMITATIONS TECHNOLOGIQUES

Michou A.I.; Christ M.; Pavirani A.; Mehtali M.

M. Mehtali, Transgene S.A., 11 Rue de Molsheim, 67000 Strasbourg France

Transfusion Clinique et Biologique (TRANSFUS. CLIN. BIOL.) (France)

1997, 4/3 (251-261)

CODEN: TCBIF ISSN: 1246-7820

DOCUMENT TYPE: Journal; Conference Paper

LANGUAGE: FRENCH SUMMARY LANGUAGE: FRENCH; ENGLISH

NUMBER OF REFERENCES: 25

...transfer protocol for haemophilia B, we constructed and tested in vitro and in vivo various recombinant adenovirus vectors expressing human FIX. Intravenous administration of this **vector** into various strains of immunocompetent and immunodeficient mice led to an efficient **hFIX gene** transfer in liver and lung. As a consequence, the hFIX protein was correctly produced and secreted at high levels in the blood of the treated

...
?

Set	Items	Description
S1	0	((FACTOR (W) IX) OR HFIX) (S) ("3' (W) UTR")
S2	0	((FACTOR (W) IX) OR HFIX) AND ("3' (W) UTR")
S3	8	((FACTOR (W) IX) OR HFIX) (S) (UTR)
S4	6	RD (unique items)
S5	3	S4 AND VECTOR
S6	3	S4 NOT S5
S7	39	(VECTOR) (S) (HFIX (W) GENE)
S8	12	S7 NOT PY>1999
S9	7	RD (unique items)

?

S S9 AND (UNTRANSLATED (W) REGION)

	7	S9
	47458	UNTRANSLATED
	2073064	REGION
	30682	UNTRANSLATED(W)REGION
S10	0	S9 AND (UNTRANSLATED (W) REGION)

?

Set	Items	Description
S1	0	((FACTOR (W) IX) OR HFIX) (S) ("3' (W) UTR")
S2	0	((FACTOR (W) IX) OR HFIX) AND ("3' (W) UTR")
S3	8	((FACTOR (W) IX) OR HFIX) (S) (UTR)
S4	6	RD (unique items)
S5	3	S4 AND VECTOR
S6	3	S4 NOT S5
S7	39	(VECTOR) (S) (HFIX (W) GENE)
S8	12	S7 NOT PY>1999
S9	7	RD (unique items)

S10 0 S9 AND (UNTRANSLATED (W) REGION)
?

COST

06oct05 13:37:29 User259876 Session D805.2
\$3.20 0.941 DialUnits File155
\$1.54 7 Type(s) in Format 3
\$1.54 7 Types
\$4.74 Estimated cost File155
\$0.81 0.257 DialUnits File159
\$0.81 Estimated cost File159
\$6.12 1.037 DialUnits File5
\$0.80 5 Type(s) in Format 95 (KWIC)
\$0.80 5 Types
\$6.92 Estimated cost File5
\$9.66 0.909 DialUnits File73
\$2.94 1 Type(s) in Format 3
\$2.94 1 Types
\$12.60 Estimated cost File73
OneSearch, 4 files, 3.145 DialUnits FileOS
\$3.20 INTERNET
\$28.27 Estimated cost this search
\$29.14 Estimated total session cost 3.371 DialUnits

?

Return to logon page!

Refine Search

Search Results -

Term	Documents
FACTOR	932821
FACTORS	751726
IX	211749
ICES	41686
IXES	3499
HFIX	207
HFICES	0
HFIXES	0
3UTR	2295
3UTRS	103
(3'UTR AND (HFIX OR (FACTOR ADJ IX))).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	91
((((FACTOR ADJ IX) OR HFIX) AND ("3'UTR")).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	91

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

Refine Search

Recall Text 

Clear

Interrupt

Search History

DATE: Thursday, October 06, 2005 [Printable Copy](#) [Create Case](#)

Set Name **Query**
 side by side

Hit Count

Set Name
 result set

DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR=YES;

OP=AND

<u>L3</u>	((Factor adj IX) or hFIX) and ("3'UTR")	91	<u>L3</u>
<u>L2</u>	((Factor adj IX) or hFIX) same ("3'UTR")	3	<u>L2</u>
<u>L1</u>	Kurachi-Kotoku.in.	11	<u>L1</u>

END OF SEARCH HISTORY



Day : Thursday
Date: 10/6/2005

Time: 13:06:00

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name

First Name

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

**PALM INTRANET**Day : Thursday
Date: 10/6/2005

Time: 13:06:00

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name**First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)